Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04725331
Recruitment Status : Recruiting
First Posted : January 26, 2021
Last Update Posted : October 22, 2021
Sponsor:
Collaborator:
BioInvent International AB
Information provided by (Responsible Party):
Transgene

Brief Summary:
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.

Condition or disease Intervention/treatment Phase
Solid Tumor, Adult Metastatic Cancer Soft Tissue Sarcoma Merkel Cell Carcinoma Melanoma Triple Negative Breast Cancer Non Small Cell Lung Cancer Biological: BT-001 Biological: Pembrolizumab [Keytruda] Phase 1 Phase 2

Detailed Description:

This study will include 3 parts:

  • Phase I, Part A: Repeated intra-tumoral (IT) administrations of BT-001 as a single agent, in patients with metastatic/advanced solid tumors; dose-escalation will be employed.
  • Phase I, Part B: Repeated IT administrations of BT-001 in combination with intravenous (IV) infusions of pembrolizumab in patients with metastatic or advanced solid tumors.
  • Phase IIa: Repeated IT administrations of BT-001 in combination with IV infusions of pembrolizumab in several cohorts of patients with defined metastatic or advanced solid tumor conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
Actual Study Start Date : February 25, 2021
Estimated Primary Completion Date : November 30, 2024
Estimated Study Completion Date : November 30, 2024


Arm Intervention/treatment
Experimental: Phase I, Part A - Dose escalation and safety of BT-001 alone
Dose escalation with repeated administrations of BT-001 directly into tumor as a single agent, in patients with metastatic or advanced solid tumors.
Biological: BT-001
Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose [Phase I, Part A] and at Recommended Dose for Part B [Phase I, Part B and Phase IIa] by intra-tumoral (IT) route.

Experimental: Phase I, Part B - Safety of BT-001 in combination with pembrolizumab
Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in patients with metastatic or advanced solid tumors.
Biological: BT-001
Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose [Phase I, Part A] and at Recommended Dose for Part B [Phase I, Part B and Phase IIa] by intra-tumoral (IT) route.

Biological: Pembrolizumab [Keytruda]
Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Experimental: Phase IIa - Expansion cohorts of BT-001 in combination with pembrolizumab
Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in several cohorts of patients with defined metastatic or advanced solid tumor conditions: soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple negative breast cancer, non-small cell lung cancer.
Biological: BT-001
Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose [Phase I, Part A] and at Recommended Dose for Part B [Phase I, Part B and Phase IIa] by intra-tumoral (IT) route.

Biological: Pembrolizumab [Keytruda]
Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.




Primary Outcome Measures :
  1. Phase I: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0) [ Time Frame: Up to 5 years ]
    Incidence of Adverse Event reported per NCI-CTCAE v5.0, Dose limiting toxicity and Serious Adverse Events.

  2. Phase I, Part A: Recommended dose for Part B (RDPB) definition [ Time Frame: Week 10-12 ]
    RDPB based on the safety data collected during the dose escalation phase (Phase I, Part A).

  3. Phase IIa (except Soft Tissue Sarcoma cohort): Immune Overall Response Rate (iORR) by iRECIST [ Time Frame: Up to 2 years ]
    Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria over the the total number of evaluable patients. for injected and non-injected lesion(s)

  4. Phase IIa (Soft Tissue Sarcoma cohort): Immune Disease Control Rate (iDCR) at 6 months by iRECIST [ Time Frame: Up to 6 months ]
    Percentage of patients whose best overall response is either a Complete Response, a Partial Response or Stable Disease according to immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria over the the total number of evaluable patients.


Secondary Outcome Measures :
  1. Phase IIa: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0) [ Time Frame: Up to 5 years ]
    Incidence of Adverse Event reported per NCI-CTCAE v5.0, Dose limiting toxicity and Serious Adverse Events.

  2. Disease Control Rate (DCR) and immune DCR by RECIST version 1.1 and iRECIST [ Time Frame: 4 months or 6 months ]
    Percentage of patients whose best overall response is either a Complete Response, a Partial Response or Stable Disease according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST over the total number of evaluable patients.

  3. Progression Free Survival (PFS) and immune PFS duration by RECIST version 1.1 and iRECIST [ Time Frame: Up to 2 years ]
    Time from the first BT-001 administration to the date of first documented tumor progression according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST or death due to any cause, whichever occurs first over evaluable patients

  4. Duration of overall Response (DoR) and immune DOR by RECIST version 1.1 and iRECIST [ Time Frame: Up to 2 years ]
    Time from the date of first documented response (CR or PR) to the date of first documented disease progression according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST or the date of death due to underlying cancer over the number of patients whose Best Overall Response is Complete Response or Partial Response.

  5. Overall Survival (OS) duration [ Time Frame: Up to 2 years ]
    Time from first BT-001 administration to the date of death due to any cause over evalauable patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have at least 1 injectable measurable cutaneous, subcutaneous or nodal lesion (direct injection or through the use of ultrasound guidance) greater or equal to 2 cm in longest diameter; or multiple injectable lesions (maximum 5) that in aggregate have a longest diameter of at least 2 cm, and whenever possible 1 distant non-injected measurable lesion.
  • Provision of a fresh tumor sample of the largest lesion that is planned to be injected and, whenever possible, the largest lesion that is planned not to be injected, at baseline and be willing to supply new tumor samples from a biopsy during treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Adequate hematological, hepatic and renal functions.

For Phase I patients:

  • Have histologically confirmed, advanced/metastatic solid tumors including non-Hodgkin lymphoma (NHL) and preferably sarcoma (soft tissue and bone), Merkel cell carcinoma, melanoma, triple negative breast cancer or non-small cell lung cancer, with cutaneous or, palpable subcutaneous lesions or easily injectable lymph nodes.
  • Have failed and/or are intolerant to standard therapeutic options.

Exclusion Criteria:

  • Have had major surgery within 4 weeks of first study drug administration.
  • Have received prior treatment with a vaccinia oncolytic virus.
  • Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or immune-suppressive medication including systemic corticosteroids.
  • History of severe exfoliative skin conditions (e.g., eczema or atopic dermatitis) requiring systemic therapy for more than 4 weeks within 2 years prior to BT-001 initiation.
  • Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social circumstances that could limit compliance with study requirements.
  • Have had a Grade ≥ 3 auto-immune manifestations of previous ICIs (e.g., anti-PD-1, anti-PDL1, anti-CTLA-4, or another immune checkpoint targeting agent under investigation).
  • Active brain metastasis (stable and treated metastasis are accepted). E8. Known hypersensitivity to egg or to any excipients of BT-001.
  • Have had any positive test for hepatitis C virus (HCV) or hepatitis B virus (HBV) indicating acute or chronic infection.
  • Pregnant or a breastfeeding woman.

For patients included in Phase I, Part B and IIa only:

  • Patient with an active known or suspected auto-immune disease. Patient with type I diabetes or hypothyroidism only requiring hormone replacement are permitted to enroll.
  • Interstitial lung disease that is symptomatic and may interfere with the detection or management of suspected drug-related pulmonary toxicity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04725331


Contacts
Layout table for location contacts
Contact: Transgene EU, Clinical Operations Department + 33.3.88.27.91.00 clinicaltrials@transgene.fr

Locations
Layout table for location information
Belgium
Clinique Universitaire Saint-Luc Recruiting
Brussels, Belgium, 1200
Principal Investigator: Pr Baurain         
France
Institut Bergonié Recruiting
Bordeaux, France, 33000
Principal Investigator: Pr Italiano         
Centre Léon Bérard Recruiting
Lyon, France, 69008
Principal Investigator: Dr Cassier         
Hôpital Saint-Louis AP-HP Recruiting
Paris, France, 75010
Principal Investigator: Pr Lebbé         
Institut Gustave Roussy Recruiting
Villejuif, France, 94800
Principal Investigator: Dr Champiat         
Sponsors and Collaborators
Transgene
BioInvent International AB
Layout table for additonal information
Responsible Party: Transgene
ClinicalTrials.gov Identifier: NCT04725331    
Other Study ID Numbers: BT-001.01
First Posted: January 26, 2021    Key Record Dates
Last Update Posted: October 22, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Transgene:
Superficial tumors
Metastatic cancer
Intratumoral
Safety
Oncolytic virus
Vaccinia virus
Solid tumors
Melanoma
Merkel
Sarcoma
TNBC
NSCLC
Pembrolizumab
BT-001
TG6030
Phase 1
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Merkel Cell
Melanoma
Sarcoma
Triple Negative Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Neoplasms by Site
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms, Connective and Soft Tissue
Breast Neoplasms
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes
Polyomavirus Infections
DNA Virus Infections
Virus Diseases
Infections
Tumor Virus Infections
Carcinoma, Neuroendocrine
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Pembrolizumab
Antineoplastic Agents, Immunological